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In the field of life sciences, biotech start-ups are expected to follow a more rapid
commercializationprocess than that experiencedbybigpharmaceutical companies.
There are about 300 public companies out of 1500 biotech start-ups in the United
States, but only 23 public companies out of about 500 biotech start-ups in Japan.
Why is there such a big numerical difference between the two countries? As a key
term, a timing option is defined as a deferrable right—like a call option—to start
anygivenproject as a real option. It is considered as auseful toolwhendetermining
the optimal timing for risky, but promising biopharmaceutical projects given the
trade-off of irreversible investments as a sunk cost. The objectives of this paper
include determining the characteristics of the optimal timing for start-ups,
understanding the model structures, and forecasting the optimal timing. As one
of findings, the dividend as an opportunity cost of waiting option can be more
important than the risk and the intensity of R&Dcompetition. Itmeans that Japan’s
start-up environment as venture capital or partnership opportunity with big
pharmaceutical firms needs to be improved.
Takao Fujiwara*
Research Paper
Application of Timing Option to Founding
Investment Decision of Biotech Start-ups
How is it basically possible to repeatedly
invest huge amounts and irreversible sunk costs
and time in new, risky, and long-term projects,
and realize a final return? Why, in the meantime,
is the number of biotech start-ups being founded
relatively low in Japan, while in the United States
new companies are constantly being founded
despite the majority being awash in red ink?
For these research questions, this paper
applies the discipline of real options analysis.
Real options analysis is the application of the
concept and techniques used for financial
derivatives to real assets. Real options analysis
can be used to evaluate the economic validity
of the innovative, promising, but high-risk project
(Copeland, 2001; Fujiwara, 2008a; Fujiwara,
2008b; Smit, 2004; Trigeorgis, 1996). That is, as
a framework integrated between biotech start-
ups and real options, the expanded net present
value produced from flexibility of real options
can often change the negative net present value
(NPV) of biotech start-ups facing with initial
negative cash flow period into the positive NPV
by hedging the downside risks and utilizing
upside chances. Thus real options can proceed
1. Introduction
About 25% of recently approved new
medicines by the National Institutes of Health
in the United States are biopharmaceuticals
(Nikkei Biotech, 2008; PhRMA, 2008). Drug-
discovery biotech start-ups are expected to refill
the gap, between basic research and clinical
development, through a more rapid
commercialization process than that experienced
by big pharmaceutical companies; however, their
bankruptcy rate is high due to resource
limitations (Kenney, 1986; National Science Board,
2008; Pisano, 2006 ) For example, while there
are about 1500 biotech start-ups and about 300
public biotech companies in the United States,
only a few dozen are profitable (Burrill and
Company, 2007). In addition, while there are
about 500 biotech start-ups in Japan, the
proportion of drug-discovery biotech start-ups
is low, and the number of public companies in
the industry is only 28—it is just the dawn of
the industry in Japan (Japan Bio-industry
Association, 2008; Venture Enterprise Center,
2008 ).
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options in the survival of biotech start-ups. For
this reason, we examine the modeling of a
symbiotic system for biotech start-ups, and
explore a suitable relationship between the
model and real options. Above all, regarding the
optimal timing of the decision to go ahead with
a start-up, a basic model of the timing option
is examined.
Japan’s Manufacturing Industrial Structure
From data obtained in 2006, the year before
the global financial crisis, we can see that Aichi
prefecture’s automobile industry is Japan’s main
manufacturing cluster (Fig. 1). Until some years
ago, there were sub-main manufacturing
clusters centered around Kanagawa’s electronic
industry and Tokyo’s publishing industry.
However, in the case of Aichi prefecture, Toyota
city’s weight of the added value of the
transportation industry has ranged from about
40 to 60%. Previously, up to 1976, prefecture’s
main industry had been textiles.
Although such a polar concentration of one
and support the survival of the risky but
innovative projects.
Above all, this paper examines the
characteristics and functions of the timing
option. This is because the timing option is an
option to defer until uncertainty levels fall, and
can be applied to an investment with irreversible,
sunk costs.
Based on the above research questions and
methodology, this article examines the necessity
of biotech cluster, basic timing-option models
that enable one to intermittently invest in new
emerging projects, and it looks at the
characteristics and functions of models that
assume underlying assets being of deterministic
or stochastic behavior with simulation results
for numerical calculations. From these models
we will find the clustering environment is very
important for increasing start-ups. 
2. The Symbiotic System of Biotech Start-
ups and the Timing Option
Here we consider the effectiveness of real
Figure 1 2006 Japan’s manufacturing industrial structure.
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conceptualized in Fig. 2 is a model based on the
functions of founding, selection, and circulation.
Although this symbiotic system is a circulation
type with feedback function, it is basically a
biotech cluster for timely screening the most
promising projects from broad opportunities,
based on a portfolio between risk and return.
Hence even a risky investment, which includes
the majority of deficit companies, can be
attractive if both the criteria of sorting precision
and improving potential are high at the
development stages for a promising portfolio.
In addition, it is also necessary to found a
company at an appropriate time, and to circulate
information, money, and human resources for
a possible re-founding through a sorting process
of product ideas, business failure, Mergers and
Acquisitions (M&A), Initial Public Offering (IPO),
and new drugs on the market.
However, in the cases of the San Francisco
Bay Area around Stanford University and
Genentech, and La Jolla around UCSD (University
of California, San Diego) and Hybritech, what
sort of decision-making criterion has already
enabled, as a trigger, many of the founding
investments in the biotech drug-discovery start-
ups, facing such severe survival conditions, even
if there already exist an excellent symbiotic
system? In other words, what kinds of
characteristics are necessary for theoretical
models and managerial techniques, to evaluate
the optimal timing of investment decisions for
the long term and large amount of irreversible
industry seems efficient for a supply chain, a
next generation of industries is necessary
through technological transfer, or the
commercialization of science research, to prevent
such high volatility and systematic shock that
comes with a financial crisis. The
biopharmaceutical industry seems one such
candidate among high-tech industries that can
exploit the commercialization of basic research
at universities throughout the country.
A symbiotic system of biotech start-ups
The number of biotech start-ups has shown
an upward trend until recently, and this is in line
with plans by the Japanese government to create
1000 start-ups across all industries by 2010. For
example, while the number of biotech start-ups
had smoothly increased from 102 companies in
1994 to 586 companies in 2006, it slightly
decreased to 577 companies in 2007 (Japan Bio-
industry Association, 2008).
Why, basically, can so many deficit biotech
start-ups survive in the United States? Can
similar results be expected here even if it is
recognized that Japan’s symbiotic system of
biotech start-ups is immature? The answers lie
in that biotech start-ups have a comparative
advantage in the more rapid commercialization
of innovative technology— even in niche
markets— than do blockbuster, drug-oriented
large pharmaceutical firms.
The symbiotic system of biotech start-ups
Figure 2 Symbiotic system of biotech start-ups: a model of founding, selection, and circulation.
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Research framework
As a definition important to the main
concept, we look at the timing option defined
as a deferrable right—like a call option—to start
any given project as a real option. As it is
mathematically understood that an American
call option should not be exercised until its
maturity, it is equivalent to a European call
option. However, the exercise of an American
call option is possible even before maturity, if
and only if the underlying asset has a dividend.
For the purposes of this research, we will assume
all business chances as the perpetual American
call options of the underlying assets with a
dividend since the numerical difference of
biotech start-ups between the US and Japan
may be unintentionally reflecting the past
exercise of such options. Then , we examine the
decision-making techniques able to overcome
the numerical difference between Japan and US
biotech start-ups under the concept of the
exercise timing of the perpetual America call
options for the underlying asset with a dividend,
related to the speed of both recognizing the
business chance and making decision of risky
investment. 
A basic model
The basic model here is based on the
precedent studies of McDonald & Siegel (1986),
Dixit and Pindyck (1994), and Mun (2002).  One
objective of the model is to develop a method
by which to solve the optimal timing of investing
a sunk cost I in the project with a value V.
Basically, all investment opportunities of a
company can be assumed as the perpetual
American call options of the underlying asset
with a dividend. Hence, the investment decision
is equal to the problem of either the exercise
timing of a perpetual American call option or
the valuation of an option to defer.
First of all, let the value of the investment
opportunity, or the option to defer, be repre-
sented by F(V) . Hence, the maximization crite-
rion of the expected present value of the invest-
ment is,
F(V) = max E[(VT - I)e-pT],
where T denotes the investment timing and
p is the discount rate. As a basic premise, when
µ is the growth rate, the dividend rate is
assumed to be µ > 0 in order to enable
the exercise of American call options. The dis-
count rate p is CAPM (Capital Asset Pricing
sunk costs, for uncertain profits? We examine
this problem next.
In order to patiently commercialize innovative
but risky projects such as biotech start-ups, it
is necessary to evaluate their potential survival
value, even that of deficit companies. At the
same time, it is also necessary to timely begin
a series of new projects without flinching even
when facing the death-valley, initial negative
cash-flow, curve. In other words, the optimal
timing of founding a start-up is vital to the
circular model of resources in the symbiotic
system working together with development /
sorting and leading to the investment exit.
In addition, if this symbiotic circular resource
system for breakthrough innovation were to be
established with some models of real options—
even in Japan—an increase of start-ups can be
expected due to a reasonable enduring of deficits
while aiming at radical innovation, in addition
to an existing incremental improvement system. 
In the following sections, we examine the
crucial component of optimal timing, based as
a timing option to defer investment until
uncertainty sufficiently decreases. This is for an
investment of irreversible sunk costs in
promising but risky projects.
A basic model of the timing option
In order to optimize the trade-off between
the irreversible investment as a sunk cost and
uncertain future profits, we examine both the
potential and the challenges of the concept and
techniques of the timing option in development
decisions. In other words, a possible reduction
of numerical gap between Japan and US biotech
start-ups is examined from an index viewpoint
of optimal investment timing.
Research question of the timing option
What kind of decision-making criteria has
already enabled much more investment in the
United States compared to Japan, with regard
toward the founding of drug discovery start-
ups in severe survival conditions, even taking
into consideration the existence of a symbiotic
system of sorting/resources circulation such as
that found in the San Francisco Bay Area? In
other words, what type of concept is needed for
a theoretical model and managerial decision-
making techniques to foster the optimal timing
of an investment that is long term and includes
a large amount of irreversible sunk costs for
uncertain profits?
(1)
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Model), which is comprised of the sum of the
dividend rate and the capital gain rate µ. The
dividend rate refers to the opportunity cost
that has occurred from the non-existence of the
underlying assets from the initial time point.
In following sections, this basic model is
expanded by separating the behavior of under-
lying assets into the deterministic and the sto-
chastic conditions.
3. The Optimal Investment Criterion in
the Deterministic Condition
A model of the optimal investment criterion
When the present value is V0, the project
value at time point t is V(t) = V0 . eµt. Then the
value of the investment opportunity at the time
point T is:
F(V) = (Vo . eµT - I)e-pT   .
If µ ≤ O, since V(t) deteriorates with time, it
is worthless to defer, so F(V) = max[V0 - I,O]. On
the other hand, if O < µ < p, since F(V) = max[Vo
e-(p-µ)T - Ie-pT ], by differentiating F(V) with
respect to T, the optimization condition is:
= - (p - µ) Voe-(p-µ)T + pIe-pT = O.
Hence, the optimal investment timing is:
T*= max {   ln[(    ) ],0}.
From the boundary conditions of lim T * = ∞
and lim T* = 0 within O < µ < p , it is neces-
sary to find equilibrium between the reduction
effect of the sunk cost and the increase of the
opportunity cost   due to the isolating from
growth of the project value by deferring the
investment. When T * = 0 in equation (3) for
deciding the exercise timing of an option to
defer, the trigger price V* of the project is: 
Vo . e-µT*  = V* = (     )I > I.
By substituting equation (4) into (2), the
optional value is:
[ (       )     ]  (        ) I   for V ≤ V*
V - I                             for V > V*.
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According to equation (6), the option value
can be specified either by the curve of the sum-
mation with the intrinsic and the time values
if the project value is equal and less than the
trigger value (critical value), or by the curve of
only the intrinsic value if the project value is
larger than the trigger value.
Numerical calculation example
When σ=0 as a deterministic situation and
T*=O is a given time point in equation (4), the
relationship between the profit index V/I and
the opportunity cost δ becomes of inverse pro-
portions (see Fig. 3). Furthermore, when p=0.1,
as opportunity cost δ becomes larger and
approaches p=0.1, the optimal investment cri-
terion V* approaches the investment I, and,
hence, the optimal exercise timing becomes ear-
lier (Fig. 4).
Therefore, at first, when the behavior of the
underlying assets can be explained by a deter-
ministic model, the relationship becomes a trade-
off between the profit index (V/I), as a ratio of
project value for investment, and the opportu-
nity cost δ , at a given level of investment tim-
ing.
Thus, the investment threshold declines with
the opportunity cost δ . Hence, when the behav-
ior of the underlying asset can be predicted
deterministically, the optimal timing point can
be calculated by both the opportunity cost and
the profit index. And the critical value as the
optimal investment criterion depends mainly
on the opportunity cost.
The Optimal Investment Criterion in
the Stochastic Condition
When the project risk is σ>O, investment tim-
ing is equated with the decision of the optimal
time point of the investment I in order to get
the asset of value V. However, it is not possible
to calculate the optimal time point T* which is
different from the deterministic condition.
Hence, after setting the critical value V* as the
trigger price, such as V ≥ V*, the timing decision
is made by observing the state variable V. When
the uncertainty of the underlying assets is mod-
eled, there exist mainly, for instance, the Geo-
metric Brownian Motion (GBM) as a basic model,
the Mean Reversion process for the long-term
average value of a project for the whole indus-
try, and the Jump process for the sudden loss
of the project value from the precedent devel-
opment completion by a potential rival or the
project failure from the toxic result at the clin-
(2)
(3)dF(V)dT
T = T
*
* *
1
µ
p
p - µ
I
V0
(4)
µ p->
µ p->
(5)pp - µ
p
p - µ V
I
p/µ
p - µ
p
(6)
F(V) =
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Figure 3 Optimal time with both profit index and opportunity cost (σ = 0).
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Figure 4 Opportunity cost and critical value (σ=0, ρ=0.1,I=1, 0< δ ≤ 0.1)
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three boundary conditions, the value of an opti-
on to defer is:
F(V)=AVβ1 
Hence, the critical value is:
V*=          I,
where,
β1 =1/2-        +   (         -1/2)2 +            > 1
A =             = 
A characteristic of the optimal criterion. A
critical value of V* an investment decision is the
project value at the tangency point between an
intrinsic-value curve and a time-value curve,
and this becomes larger with an increase in risk
σ (see Fig. 5). As a difference between an option
value and an intrinsic value, the time value [F(V)-
(V-I) ≥ O] enlarges with the increase of risk σ,
and this makes the level of the profit index, V/I
= 1 , a peak (see Fig. 6). For a given critical value
V*, there is a trade-off between the largeness
of risk σ and the smallness of opportunity cost
δ (see Fig. 7). And for a given risk σ, the critical
value V*declines with the increase of opportu-
nity cost δ; this makes the exercise timing
becomes earlier (see Fig. 8). 
Thus, at first, if risk is small, it is a time value
in optional value contracts. Also, it is considered
a critical value V*approach to an investment I
as an exercise price when the optional value is
equal to the Net Present Value (NPV). In this
case, the additional time value to an intrinsic
value becomes zero. Next, the size of a time
value, in the design or exercise of a real option,
increases with the largeness of risk around the
grey zone, where the NPV is close to zero or the
profit index =1 (since the project value is equal
to the investment). That is, real options can work
most effectively, and the relation of real options
with parameters is significantly efficient, in
transforming the NPV into the ENPV (Expand-
ed NPV). Thirdly, critical value V*as a criterion
of investment timing can be determined as a
trade-off between the largeness of risk σ and
the smallness of opportunity cost δ. Finally, a
related matter, if the risk σ is constant and the
opportunity cost δ increases, the critical value
V*declines. In this case, the timing is likely to
come earlier. In addition, it is possible to spec-
ify the critical value V* from the parameters of
curves. Since it is impossible to calculate the
optimal timing based on the stochastic assump-
tion of the underlying assets, stochastic opti-
mal timing is forecasted by replicating a time
ical trial.
A case of the GBM model of the underlying
assets
A theoretical model. If you assume the uncer-
tainty of the underlying asset V as a GBM with
the drift parameter µ, the volatility σ , and the
Weiner process dz, the random walk equation
is:
dV = µ V dt + σ V dz.
The value F(V) of an option to defer as an
investment opportunity has, by reflecting the
time value and the intrinsic value, the bound-
ary conditions as follows:
F(O) = O,
F (V*) = V* - I,
F’ (V*) = 1,
For the exercise timing of an option to defer,
it is a premise that the critical value V* of a proj-
ect is the summation of the exercise cost I and
the option value F(V*) as the opportunity cost
of an investment without deferring. Hence, it
can be said that for V, under the condition of
F(V) ≥ V* - I , it is too early for the exercise, and
for V under the condition of F(V) < V* - I , it is
the optimal timing.
Both the methods of Dynamic Programming
(DP) and Contingent Claims Analysis (CCA) can
be proved to reach the same solution. In the
case of DP, the assumption is that the return of
the investment opportunity F with interest p
and time increment dt is equal to the expect-
ed variation of asset value of the investment
opportunity:
ρF dt = E [dF].
On the other hand, with CCA, total return of
the risk-free dynamic portfolio consists of the
investment option F(V) and F’(V) the   unit of
short position of the asset, which, in need of
the unit time maintenance cost δVF’ (V), is
dF-F’(V) dV - δVF’ (V) dt.
From each assumption, applying Ito’s lemma,
the differential equation is:
σ2 V2 F’’(V) + (ρ-δ) VF’ (V)-ρF = O
If one solves this equation under the above
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
β1
β1 -1
(15)
ρ - δ
σ2
ρ - δ
σ2
2ρ
σ2
(16)
V* - I
(V*) β1 
(β1 - 1) β1 - 1 
β1 β1 I β1-1
(17)
1
2
Takao Fujiwara
Journal of Business Chemistry 2011, 8 (3)© 2011 Institute of Business Administration 140
Figure 5 Option value and risk ( ρ=0.1, I=1).
Figure 6 Option value with profit index and risk (ρ=0.1, I=1).
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Figure 7 Critical value of risk and opportunity cost (ρ=0.1, I=1).
Figure 8 Critical value with risk and opportunity cost (ρ=0.1, I=1).
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point within the project value (as a state vari-
able) with one equal as bigger than the critical
value as V ≥ V*. 
Simulation. Here, the measurement of the
optimal timing of an investment is examined
using a Crystal Ball simulation of the numeri-
cal computation of the time point when the
project value V, as a state variable, becomes
equal or larger than the critical value V*. This is
a modeling of the volatility risk of the underly-
ing asset using GBM.
For instance, when base case parameters are
following; annual interest p = 0.3, growth rate
µ = 0.05, dividend = 0.05, risk σ = 0.6, and
investment I = 1, a simulation result shows that
each optimal timing of base case T = 402nd day,
of larger volatility T(σ = 0.75) = 387th day, and
of larger dividend T( = 0.25; σ ) = 283rd
day  (250 annual working days) (see Fig. 9). At
the same time, from each asset critical value of
base case V* = 10,00, of larger volatility V* = 12.13,
and of larger V = 2.42 with each probability
curve, it is expected that the dividend can make
much earlier the timing with lower critical value,
and the volatility can make it a little earlier with
higher probability regardless of higher critical
value respectively than the base case dose on
the 750th day (see Fig. 10). 
Thus both the critical value and the proba-
bility distribution are important to forecast the
optimal investment timing by using simulation.
Especially the dividend as opportunity loss with
waiting can make considerably earlier the invest-
ing timing. 
Additionally, the volatility has to be moni-
tored by not only critical value but also proba-
bility distribution (probably necessity of repeat-
ed simulation trials). 
A case of the jump diffusion model of the
underlying assets.
A theoretical model. Here we expand the
GBM model as a basic model of an underlying
asset’s behavior into the Jump Diffusion Model
by adding the Poisson Jump process. As an exam-
ple, let the immediate value change of a proj-
ect that is deferring but facing the risk of prece-
dent development and market monopoly by a
potential rival or the risk of toxic failure in a
clinical trial be represented as
dV = µ V dt + σ V dz - V dq,
where dq is an increment of the Poisson
process with the average arrival rate λ, and an
adjustment of dV by -ΦV with the probability
λ dt (0 ≤ Φ ≤ 1). According to Merton’s proof (Mer-
ton, 1990), it becomes possible to add dq to ran-
dom walk equation (7) and convert it into (18).
Hence: 
dq = {
F(V), A, V* each have the same equation, as
with the case of GBM, but whenΦ = 1, the euqa-
tion of β1 becomes 
β1 =         -          +              -       +                .
Because of the fact that when Φ = 1, the dec-
line rate -Φ of a project value makes the project
value equal to zero using V - V from equation
(18) , there is a decrease in the opportunity cost
of the immediate investment without defer-
ring—there is a decline in the critical value as
a trigger price, and this has the effect of has-
tening the investment. Thus, in an option to
defer with the hope of a decrease in uncertain-
ty, the jump diffusion process assumes the trade-
off between the decrease in uncertainty and the
risk of a sudden precedent development by a
potential rival or the risk of toxic failure of clin-
ical trial by adding the Jump process into the
basic GBM model of the underlying assets.
Hence, it is necessary to replicate the optimal
timing with a simulation that takes into effect
a stochastic balance between the effect of an
uncertainty reduction by deferring an invest-
ment and the risk to completely and suddenly
lose the value of a project.
Simulation. With a simulation based on a
numerical calculation, it is possible to test the
validity of a decision on the optimal investment
timing by comparing a state variable of project
value with its critical value. For example, from
a simulation result that includes the base case
parameters of volatility σ = 0.7, driftµ = 0.25,
discount rate p = 0.3, investment I = 1, average
arrival rate λ = 0.005, and change rate of the
Poisson process Φ = 1, we see that each optimal
timing of base case T(λ = 0.005) = 313th day, of
higher dividend T(λ = 0.005; = 0.25) = 126th
day, and of GBM T(λ = 0) = 350th day (per 250
annual operating days) (see Fig. 11). And the ana-
lysis of critical values of waiting option and pro-
bability distribution curves on the 750th day
shows that the jump-diffusion process as a sort
of competitive R&D game significantly changes
the each probability distribution curve, makes
a little earlier the investment timing and addi-
tion of dividend makes considerably earlier it
Takao Fujiwara
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Figure 9 A comparison of timing by GBM simulation with and σ (Base case: V0 = 1, I = 1, p = 0,3, µ = 0.25, = 0.05, 
σ = 0.6).
Figure 12 Probability of asset critical value and timing on 750th day at GBM process.
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Figure 11 A comparison of timing by jump diffusion simulation with and λ (Base case: V0 = 1, I = 1, p = 0.3, µ = 0.25, 
= 0.05, σ = 0.7, λ = 0.005).
Figure 12 Probability of asset critical value and timing on 750th day at GBM process.
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than GBM does (see Fig.12). 
Then the intensity of R&D competition can
reduce the value of investment waiting by pro-
bability distribution curves and sudden disap-
pearance of project value. Basically jump-diffu-
sion process can make a little earlier the invest-
ment timing by critical value calculated, com-
pared with GBM. Additionally the dividend also
can significantly make earlier the timing by redu-
cing the critical value.
Therefore, between the US and Japan condi-
tions, the US has more excellent and favorable
incubating condition as clusters of biotech start-
ups as VCs, medical schools, and partnership
opportunities with big pharmaceutical firms
than Japan does. It means higher dividend as
waiting loss of investment. And the US has 1500
biotech start-ups comparing with Japan’s 500
similar firms. This type of competitive R&D inten-
sity can facilitate to reduce critical value of
investing. Hence, the US main biotech clusters
have reached the critical mass as positive feed-
back threshold. 
For Japan’s future scenarios to cope with the
rapid aging problem, first of all, it is necessary
to establish more excellent clusters of biotech
start-ups or cooperate with the US biotech clu-
ster for them with expanding the social tole-
rance to risk taking for biotech entrepreneurs.
Then she needs to draw roadmap to immedia-
tely reach the critical mass. 
Thus real options method seems very useful
analytical and managerial tool as the risk con-
trol method and the working definition of start-
ups. We checked here just the simple simulati-
on examples. Furthermore in the future, it still
seems necessary to make predictions that con-
form with a forward-looking process that goes
beyond starting a project that relies only on exi-
sting spot forecasting, and, furthermore, to focus
on only the most profitable opportunity while
forecasting.
4. Conclusion
The reason why a lot of deficit companies
facing the death-valley curve can survive in the
United States depends on a rational decision
making process based on whether the return as
a whole is larger than the investment. That is,
their survivals depend on the flexibility of invest-
ment decision as real options by treating a sunk
cost through milestone investment, government
grants into basic research, partnership oppor-
tunities with big pharmaceutical firms, and tax
shields for investors. There are also symbiotic
systems called biotech clusters to support, incu-
bate, and circulate resources within clusters for
the founding of biotech start-ups, as in the San
Francisco Bay Area and La Jolla. The efficiency
of these biotech clusters also can influence on
the value of real options for biotech start-ups.
Furthermore, the timing option as one of real
options is applicable to the decision to found a
start-up as an irreversible investment of a huge
amount of sunk costs into a long-term and high-
risk project. The efficiency of biotech cluster as
incubation and partnership opportunities with
big pharmaceutical firms is related with the
dividend as opportunity loss by waiting invest-
ment. On the other hand, the intensity of R&D
competition can be modeled by using jump-dif-
fusion process. Thus it is also applicable in hel-
ping to reduce the numerical difference of bio-
tech start-ups between Japan and the United
States , theoretically by using some  parame-
ters as a dividend and jump-diffusion process
and practically by improving the efficiency of
biotech clusters and the opportunity of open
innovation.
The models and simulation techniques
examined here may contribute to the foreca-
sting of the optimal timing of founding start-
ups, and to the improvement of Japanese mana-
gement style, which is generally regarded as
making slow, prudent decision, by calling atten-
tion to the importance of opportunity loss in
addition to the value of the option to defer
investing in the projects of biotech start-ups,
based on more objective and quantitative
methods. However, not only competitive models
as jump-diffusion process but also open-inno-
vation model is needed to study by using opti-
on-games analysis, integrated between real opti-
ons and game theory. Additionally an estimate
based on the probability distribution using mul-
tiple trials also seems to be necessary, instead
of relying only on simulation as the one scena-
rio for timing forecasting. Furthermore, in the
future, there may still be challenges in expan-
ding the biotech start-up model. It will depend
on characteristics such as intellectual property,
the switching options of market entran-
ce/withdrawal, the learning effect, and the decay
of competitiveness due to obsolescence. And
modeling the biotech entrepreneurship as the
mind set to risk is also necessary for high risk
but innovative start-ups by bridging between
basic life science and new medical treatments.
References
Burrill and Company (2007): Biotech 2007, Burrill &
Company, San Francisco, CA.
Copeland, T. and Antikarov, V. (2001): Real Options: A
Journal of Business Chemistry 2011, 8 (3) © 2011 Institute of Business Administration 
Application of Timing Option to Founding Investment Decision of Biotech 
Start-ups
145
Practitioner's Guide, Texer, New York.
Dixit, A.K. and Pindyck, R.S. (1994): Investment under
Uncertainty, Princeton University Press, Princeton,
NJ.
Fujiwara, T. (2008a): Japan’s health-care service and the
death-valley strategy of biotech-sturt-ups, Global
Journal of Flexible Systems Management, 9(1), p.1-
10.
Fujiwara, T. (2008b): Modeling of strategic partnership
of biotechnological start-up by option-game: aiming
at optimization between flexibility and commitment.
Journal of Advances in Management Research, 5(1),
p.28-45.
Japan Bio-industry Association (2008): 2007 Bio-industry
Study Report, Japan Bio-industry Association, Tokyo,
Japan (in Japanese). 
Kenney, M. (1986): Biotechnology: The University-Industrial
Complex, Yale University Press, New Haven, CT.
McDonald, R. and Siegel, D. (1986): The value of waiting
to invest. Quarterly Journal of Economics, 1014
(November), p.707-728.
Merton, R.C. (1990): Continuous-Time Finance, Blackwell,
Cambridge, MA.
Ministry of Economy, Trade and Industry (2008): Industrial
Statistical Tables, Government Printing Office, Tokyo,
Japan (in Japanese).
Mun, J. (2002): Real Options Analysis, Wiley, Hoboken,
NJ.
National Science Board (2008): Science and Engineering
Indicators 2008, National Science Foundation,
Arlington, VA.
Nikkei Biotech (2008): Nikkei Biotech Yearbook 2008,
Nikkei BP, Tokyo, Japan, (in Japanese).
Pharmaceutical Research and Manufacturers of America
(2008): Pharmaceutical Industry Profile 2008, PhRMA,
Washington, DC.
Pisano, G.P. (2006): Science Business: The Promise, the
Reality, and the Future of Biotech, Harvard Business
School Press, Cambridge, MA.
Smit, H.T.J. and Trigeorgis, L. (2004): Strategic Investment:
Real Options and Games, Princeton University Press,
Princeton, NJ.
Trigeorgis, L. (1996): Real Options: Managerial Flexibility
and Strategy in Resource Allocation, MIT Press,
Cambridge, MA.
Venture Enterprise Center (2008): 2007 Venture Capital
Investment Report, Venture Enterprise Center, Tokyo,
Japan (in Japanese).
Takao Fujiwara
146
